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Abstract.  The proliferation of arterial smooth muscle 
cells (SMCs) plays a critical role in the pathogenesis 
of arteriosclerosis. Previous studies have indicated that 
the glycosaminoglycan heparin specifically inhibited 
the growth of vascular SMCs in vivo and in culture, 
although the precise mechanism(s) of action have not 
been elucidated. In this study, we have examined the 
ability of specific mitogens (PDGF, EGE heparin- 
binding growth factors, phorbol esters, and insulin) to 
stimulate SMC proliferation. Our results indicate that 
SMCs derived from different species and vascular 
sources respond differently to these growth factors. We 
next examined the ability of heparin to inhibit the 
proliferative responses to these mitogens. In calf aortic 
SMCs, heparin inhibits a protein kinase C-dependent 
pathway for mitogenesis. Detailed cell cycle analysis 
revealed several new features of the effects of heparin 
on SMCs. For example, heparin has two effects on the 
Go--"S transition: it delays entry into S phase and also 
reduces the number of cells entering the cycle from 
Go. Using two separate experimental approaches, we 
found that heparin must be present during the last 4  h 
before S phase, suggesting a mid-to-late G~ heparin 
block. In addition, our data indicate that heparin- 
treated SMCs, while initially blocked in mid-to-late 
G,, slowly move back into a quiescent growth state in 
the continued presence of heparin. These results sug- 
gest that heparin may have multiple targets for its an- 
tiproliferative effect. 
ERI~^NT regulation  of cell proliferation  plays an im- 
portant role in many disease processes,  including 
cancer, psoriasis,  retinopathies,  certain glomerular 
nephritides,  and arteriosclerosis.  For example, the hallmark 
of early atherogenesis is a proliferation of arterial smooth 
muscle cells (SMCs),.~ Because of this the focus of much of 
the recent research in the pathobiology of the vascular wall 
has examined the cellular and molecular mechanisms that 
promote SMC growth (Ross, 1986). Particular emphasis has 
been placed on the identification of peptide mitogens which 
bind to cell surface receptors, and the sequence of  events they 
initiate that results in SMC proliferation.  The mitogenic re- 
sponse of murine mesenchymal cells appears  to involve at 
least two postreceptor pathways (Ran et al.,  1986; McCaf- 
frey et al., 1987). One pathway is dependent on protein ki- 
nase C (PKC) and is activated by PDGF, bombesin, phorbol 
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esters,  and thrombin.  The other pathway is dependent on 
cAMP and calcium, and is activated by EGE 
It is  clear,  however, that stringent control mechanisms 
must also exist for regulating the response to mitogenic stim- 
uli, since the proliferation of most cells is tightly controlled 
(Sager, 1986). Several molecules have been described in the 
last  few years that can inhibit  the growth of various  cell 
types, including retinoic acid (Lotan and Nicolson,  1977), 
interferons (Lengyel, 1987), transforming growth factor-15 
(Roberts et al., 1985), and heparin (Castellot et al.,  1987). 
Heparin is a structurally complex glycosaminoglycan com- 
posed of repeating disaccharide units of alternating glucosa- 
mine and uronic acid sugars. Previous work from this labora- 
tory demonstrated  that heparin could inhibit the proliferation 
of SMCs and other selected cell types in vivo (Clowes and 
Karnovsky, 1977; Guyton et al., 1980) and in vitro (Hoover 
et al., 1980; Castellot et al., 1981). Heparin has been shown 
to bind to the SMC surface, and is subsequently internalized 
(Castellot  et al.,  1985b). Other effects of heparin include 
changes in cell cycle kinetics  (Castellot  et al.,  1985a),  al- 
tered protein synthesis and secretion (Cochran et al., 1985; 
Majack and Bornstein,  1984; Clowes et al.,  1988), inhibi- 
tion of motility (Majack and Clowes, 1984), and modulation 
of the antiproliferative activity by extracellular matrix (Her- 
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model system, we have recently shown that heparin inhibits 
a protein kinase C--dependent mitogenic pathway activated 
by phorbol esters, but has little effect on the EGF-dependent 
growth pathway (Wright et al.,  1989). 
We report here a detailed analysis of the effects of heparin 
on the SMC cell cycle. We have also examined the effect of 
heparin on the ability of specific mitogens to stimulate the 
proliferation of different species and sources of SMCs, in- 
cluding human cells. The results indicate that heparin in- 
hibits a PKC-dependent pathway in calf aortic SMCs, and 
further suggests that heparin may have multiple targets for 
its antiproliferative mechanism of action. 
Materials and Methods 
Materials 
Tissue culture plastics were from Falcon Labware, Becton, Dickinson & 
Co. (Oxnard, CA) or NUNC, and media and calf serum were from Flow 
Laboratories,  Inc.  (McLean,  VA).  Plasma-derived serum was prepared 
from human donor blood as previously described (Pledger et al.,  1977). 
Heparin used for these studies was the sodium salt derived from porcine 
mucosa with a molecular weight of 12,000-18,000  and was obtained from 
the Institute Choay (Paris, France). Radioisotopes were obtained from New 
England Nuclear (Boston, MA).  Restriction enzymes were from Boehr- 
inger Mannheim Biochemicals (Indianapolis, IN). Phorbo112-myristate 13- 
acetate (TPA), isobutylmethylxanthine, and molecular weight markers were 
from Sigma Chemical Co. (St. Louis, MO); EGF (receptor grade) was from 
Collaborative Research (Lexington, MA);  PDGF was from PDGF Inc., 
Boston, MA; cholera toxin was from Behring Diagnostics American Hoechst 
Corp. (San Diego, CA); and recombinant human acidic and basic fibroblast 
growth factor (aFGF and bFGE respectively) was generously supplied by 
Drs. S. Thompson, J.  Rose, and E. Tischer of California Biotechnology, 
Inc. (Mountainview, CA). 
Smooth Muscle Cell Culture 
All cells were cultured at  37°C  in  a  humidified,  5%  C02/95%  air  at- 
mosphere. All growth media contained 4 mM glutamine, 100 #g/ml penicil- 
lin, and  100 p,g/ml streptomycin. 
Rat aortic SMCs from Sprague-Dawley rats (CD strain; Charles River 
Breeding Lahoratories, Wellesley, MA) were isolated, cultured, and charac- 
terized as previously described (Hoover et al., 1980; Castellot et al., 1982). 
Briefly, the abdominal segment of the aorta was removed and the fascia was 
cleaned away under a dissecting microscope. The aorta was cut longitudi- 
nally and small pieces of  media were carefully stripped from the vessel wall. 
Two or three such strips were placed under small stainless steel mesh 
screens in 60-mm tissue culture dishes. Within 1-2 wk, SMCs migrate from 
the explants; they were capable of being subcultured about a week after the 
first appearance of cells. They were grown in RPMI 1640 medium contain- 
ing 20%  FCS. 
Calf aortic SMCs were isolated from explants of bovine aortas as de- 
scribed by Ross (1971). They were grown in high glucose (4,500 mg/ml) 
DME containing 10%  calf serum. 
Human saphenous vein SMCs were kindly provided by Dr. Peter Libby 
(Tufts  University School of Medicine). They were grown in low glucose 
(1,500 mg/ml) DME buffered with 25 mM Hepes and containing 10% FCS. 
All SMC types were identified as smooth muscle cells by the presence 
of (a) numerous myofilament bundles in the cytoplasm, (b) numerous vesi- 
cles near the plasma membrane, (c) SMC-specific myosin, as revealed by 
indirect immanofluorescence (Larson et al., 1984), and (d) the characteris- 
tic "hillocks and valleys" appearance of confluent cultures. 
Growth Arrest of Cells 
To growth arrest SMCs, sparsely plated cultures were washed and placed 
in basal medium (i.e., either RPMI or DME, as described above) containing 
0.5% PDS or 0.4% FCS for 72 h. Flow microfluorimetry and determina- 
tions of [3H]thymidine-labeled nuclei  indicated that  >95%  of the cells 
were arrested in Go(GO. 
Cell Proliferation  and Inhibition Assays 
To assay for the effects of mitogens and heparin on cell growth, 5-10 x  103 
SMCs were plated into 16-mm multiwell plates in normal growth medium. 
After 24 h, they were growth arrested as described above. Control SMC cul- 
tures  were  released  from  Go  by  placing  them  in  their  normal  growth 
medium. Replicate cultures were treated with normal growth medium con- 
mining heparin.  Other SMC cultures were exposed to basal medium  + 
0.5 % PDS containing various mitogens in the presence or absence of hepa- 
rin. Three methods were used to assess mitogenesis or growth inhibition: 
cell counting, determination of the fraction of [3H]thymidine-labeled nu- 
clei, and DNA synthesis measurements. 
Cell  numbers  were  measured  in  triplicate  samples using  a  counter 
(Coulter Electronics Inc., Hialeah, FL), and trypsinized cultures were rou- 
tinely checked by direct microscopic examination to ascertain that the tryp- 
sinization procedure had not lysed the cells and to ensure that all cells were 
removed from the multiwell. The cells were not fed during the experiment. 
The net growth of SMCs in control cultures was obtained by subtracting the 
starting cell number (at the time the cells are released from Go) from the 
cell number at the end of the experiment. The net growth of SMCs in 
heparin-containing medium is computed in a similar fashion. The degree 
of inhibition is determined from the following relationship: 
% inhibition =  1 -  net growth in heparin  ×  100 
net growth in controls 
The fraction of labeled nuclei was determined using growth-arrested sub- 
confluent SMCs in 35-mm dishes (5-7  ×  104/dish)  which were labeled 
with  [3H]thymidine (2  /zCi/ml;  80 mCi/nmol) in the presence of basal 
medium  +  0.5%  PDS containing purified mitogens at 37°C for varying 
lengths of  time, depending upon the experiment. After labeling, the cultures 
were rinsed extensively in PBS, fixed in 3.7%  formaldehyde for 30 rain, 
treated with methanol for 15 min, and air dried, all at room temperature. 
The  cultures  were  then  processed  for autoradiography  using  emulsion 
(NTB-2; Eastman Kodak Co., Rochester, NY). The percentage of labeled 
nuclei was determined in triplicate cultures for at least 200 cells per dish. 
DNA  synthesis  was  determined by  measuring  the  incorporation  of 
[3H]thymidine into TCA-precipitable material as follows: SMCs plated and 
growth  arrested  in  16-ram  multiwells were exposed to  normal  growth 
medium or to basal medium +  0.5% PDS containing mitogens to which 5 
/zCi/ml [3H]thymidine bad been added.  SMCs were labeled for varying 
lengths of time, depending on the experiment. At the end of the labeling 
period, the cells were washed twice with cold PBS. After washing,  1 ml 
10 % TCA was added to each well for 30 min at 4°C. The TCA was aspirated, 
and the cells were washed four times with cold 10% TCA.  Residual TCA- 
precipitated label was extracted with 0.2 N NaOH and the level of radioac- 
tivity was determined by liquid scintillation counting. 
Flow Microfluorimetry 
DNA histograms were obtained by flow microfluorimetric analysis of cells 
stained with a hypotonic solution of propidium iodide (50/~g/ml propidium 
iodide in 0.1% sodium citrate), according to standard methods (Yen et al., 
1977). Cells were washed three times with staining solution, and incubated 
in the propidium iodide solution for 2 h at 4°C. Nuclei were harvested by 
gentle pipetting and analyzed within 4 h on a FACS II (Falcon Labware, Bec- 
ton, Dickinson, &  Co., Oxnard, CA). 
Results 
Cell Cycle Analysis 
The cell cycle studies described below were designed to an- 
swer  three  questions  about  the  antiproliferative effect of 
heparin on vascular SMCs: (a) What is the effect of heparin 
on the kinetics of the Go~S transition? (b)  Where are the 
heparin-sensitive points in the cell cycle? and (c) What is the 
cell cycle distribution of SMCs after exposure to heparin? All 
of these experiments used subconfluent, low-serum arrested 
SMCs and examined the first cell cycle traverse after release 
from Go. 
Effects  of Heparin  on  the Go~S  Transition.  Because 
previous flow microfluorimetric studies suggested that hepa- 
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Figure 1. Heparin has two effects on the Go~S transition. Calf (A) 
or rat (B) aortic SMCs were growth arrested in low serum for 72 h, 
as described in Materials and Methods. The cells were then re- 
leased from the Go block by incubating them in medium contain- 
ing 5 /zCi/ml [3H]thymidine and either  10% calf serum or 20% 
FCS with or without 200 #g/ml heparin. At the indicated times, 
cells were fixed, processed for autoradiography, and the fraction 
of labeled nuclei was determined as described  in Materials and 
Methods. 
rin altered the kinetics of the Go--'S transition (Castellot et 
al.,  1985a),  we characterized tl-~is effect in greater detail 
(Fig.  1). Growth-arrested rat and calf aortic SMCs were re- 
leased from the Go block by placing them in normal growth 
medium in the presence or absence of 200 #g/ml heparin, 
a dose that resulted in 75-85 % inhibition of SMC prolifera- 
tion as measured in cell counting assays on replicate cultures 
in the same experiment. At this dose of heparin, two effects 
were observed. Approximately 50% of the cells do not enter 
S phase; the other half do enter S phase, but enter with an 
8-h lag compared to control cells. At lower doses of heparin 
(10-100 #g/ml) the delayed entry phenomenon was still ob- 
served, although the length of the delay was somewhat more 
variable at 10 #g/ml (from 4 to 8 h; data not shown). Lower 
concentrations of heparin also allowed more cells to enter S 
phase:  at  100 #g/ml,  71%  of the SMCs  entered S phase, 
whereas at 10 #g/ml, 83% of the cells entered S phase, es- 
sentially the same as in control cultures (data not shown). At 
higher doses of heparin (400 #g/ml), only 12% of the cells 
were able to enter S phase.  This concentration of heparin 
resulted in >90% inhibition of SMC proliferation as deter- 
mined using cell counting assays of replicate cultures in the 
same experiment. SMCs were still viable after exposure to 
this  heparin concentration as  demonstrated by a  standard 
Trypan blue assay.  Thus, heparin exerts two effects on cell 
cycle traverse in SMCs; a reduction in the fraction of cycling 
cells, and delayed entry into S phase. These data also suggest 
that heparin may be able to affect SMC growth either at sev- 
eral distinct sites within the cell cycle or that it has two differ- 
ent effects at a  single site.  Interestingly, these effects may 
show differing sensitivities to heparin since the ability of 
heparin to reduce the number of cells entering S phase ap- 
pears to require a higher concentration than does the delayed 
entry phenomenon. 
Heparin-sensitive  Points  in  Gt.  Previous  studies  on 
SMC cell cycle kinetics after heparin treatment suggested the 
presence of a late Gt block (Castellot et al.,  1985a). In con- 
trast, reports of a mid-G~ heparin-sensitive point in human 
(Seldon, S. C., unpublished data) and primate (Kenagy, R. D., 
and A. W. Clowes, unpublished data) SMCs, and our own 
observations that rat cervical epithelial cells (RCECs) are 
blocked in early G, by heparin (Wright et al.,  1985), and 
that  early  G,  events  such  as  induction  of the  protoon- 
cogenes c-fos and c-myc in BALB/c fibroblasts are affected 
by heparin (Wright et al.,  1989) suggest the possibility of a 
very early heparin-sensitive point. We therefore undertook 
two separate experimental approaches to carefully determine 
the heparin-sensitive point in the G, phase of the SMC cell 
cycle. 
The first approach was to carry out "delayed addition" ex- 
periments (Fig. 2). In these studies, quiescent rat and calf 
SMCs were released from growth arrest by placing them in 
normal growth medium. At the indicated times after release 
from Go, 200 #g/ml heparin was added to the cultures, and 
the ability of these cells to synthesize DNA was measured. 
Cell counting was also performed to ensure that the changes 
observed in  DNA  synthesis  correlated with  reduced cell 
proliferation. In both rat and calf aortic SMCs, the addition 
of heparin could be delayed until ,,04 h before S phase and 
still inhibit the incorporation of [3H]thymidine into DNA. 
If added during the last 4 h of G,, heparin became rapidly 
less effective. 
The second approach to determine where in the cell cycle 
heparin blocks SMCs is based on the work of Campisi and 
Pardee (1982) to determine the serum-sensitive point in the 
G~ phase of BALB/c fibroblasts. The experimental rationale 
is as follows: if cells require a growth stimulus until a certain 
point  in  G~,  then any cells  in  an  exponential population 
which are beyond this point should continue to cycle and will 
enter S phase even after the growth stimulus (for example, 
serum)  is  withdrawn,  whereas  cells  which  have  not  yet 
reached the sensitive point when the stimulus is removed will 
not traverse the block point and will not begin DNA synthe- 
sis. Thus, the fraction of labeled nuclei will continue to in- 
crease until all the cells which were past the sensitive point 
have entered S phase, at which time the labeled nuclei frac- 
tion will level off. The length of time that the labeled nuclei 
fraction continues to increase after withdrawing the growth 
stimulus represents the temporal distance between the block 
point and S phase. For serum stimulation of BALB/c fibro- 
blasts, the serum-sensitive point was located '~2 h before S 
phase (Campisi and Pardee, 1982). In our experiments, we 
added a growth inhibitor (200 #g/ml heparin) to rat aortic 
SMC to mimic the action of withdrawing a mitogenic stimu- 
lus (Fig. 3). For comparison, we also removed serum from 
these cells. The labeled nuclei fraction continued to increase 
for 2-4  h  after adding  heparin.  Interestingly,  the  serum- 
sensitive point in SMC also appears to be located 2-4 h be- 
fore S phase. These data corroborate in an independent fash- 
ion the finding of a  heparin-sensitive point in mid-to-late 
G~, approximately 4  h before the onset of DNA synthesis. 
Cell Cycle Position of SMCs after Exposure to Heparin. 
There is little data to indicate the cell cycle position of SMCs 
which have been exposed to heparin for prolonged periods. 
Flow microfluorimetry  of SMC treated with 100 #g/ml hepa- 
rin for 72 h indicates that >90% of the cells are in G, (Fig. 
4, inset; similar data reported in Castellot et al., 1985a). To 
more carefully determine the cell cycle position of SMCs 
treated  with  heparin  for prolonged  periods,  we  exposed 
growth-arrested rat aortic SMCs to normal growth medium 
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Figure 2. Delayed addition of 
heparin  indicates  a  heparin- 
sensitive  point  in  late  G,. 
Growth-arrested  calf  (.4) or 
rat (B) SMCs were placed in 
normal  growth medium con- 
raining  5  #Ci/ml  [3I-I]thymi- 
dine.  At  the  indicated  times 
after  release  from  Go,  200 
~tg/ml heparin  was  added  to 
the  cultures.  The cells  were 
processed  for  autoradiogra- 
pby at 48 and 96 h for the de- 
termination of labeled nuclei. 
Cell counting assays were per- 
formed at 96 h to ensure that 
the changes observed in DNA 
synthesis correlated  with  re- 
duced cell proliferation. 
containing  100 ~tg/ml heparin for 24, 48, or 72 h (Fig. 4). 
At these times, the heparin-containing medium was removed 
and replaced with normal growth medium containing [3H]- 
thymidine  without  heparin.  At  the  indicated  time points, 
both  [aH]thymidine incorporation into DNA and the frac- 
tion  of labeled  nuclei  were determined.  Both  approaches 
yielded similar results; only the DNA synthesis data is shown 
for simplicity. SMCs exposed to heparin for 24 h entered S 
phase without any appreciable delay after removal of hepa- 
rin, as shown in Fig. 1 B and Fig. 4. SMCs treated with hepa- 
rin for 48 h demonstrated a significantly slower rate of entry 
into S phase after washing off  the heparin-containing medium. 
After 72 h of exposure to heparin, SMCs required ,x,16 h to 
begin DNA synthesis after the heparin was removed. This is 
essentially the  same time required  for growth-arrested rat 
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Figure  3. One heparin-sensitive  point is 2-4 h before S-phase. Ex- 
ponentially growing cultures of rat aortic SMCs were incubated in 
medium containing 20% FCS and 5 ttCi/ml [3H]thymidine with or 
without 200 #g/ml heparin.  At the indicated times, the cells were 
processed  for autoradiography  and the fraction of labeled nuclei 
was determined.  For comparison,  we also replaced the 20% FCS- 
containing  medium with medium containing 0.4%  FCS.  Similar 
results were obtained with calf aortic SMCs (not shown). 
aortic SMCs to enter S phase in the absence of heparin (F~g. 
1 B), and suggests that SMCs do not remain blocked at the 
heparin-sensitive point 2-4 h before S phase, but move slowly 
back into the quiescent (i.e., Go) state. 
It is possible that cells exposed to heparin for 48 or 72 h 
may escape the late G~ block, traverse the rest of the cell 
cycle,  and  arrest  again  in  Go.  If this  were  the  case,  the 
SMCs would go through S phase and the fraction of labeled 
nuclei  in  heparin-treated  cells  would  slowly  increase  be- 
tween 24  and 72  h  until  the control  values were reached 
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Figure 4.  Heparin-treated SMCs  move  slowly back into Go. 
Growth-arrested rat aortic  SMCs were released  from Go by in- 
cubating  them in  medium containing  20% FCS with  (o, e, 4) or 
without  (x)  200 ~tg/ml  beparin.  After  24,  48, or  72 h, the  beparin- 
containing  medium was removed and replaced  with  heparin-frcc 
medium containing  20% FCS and 5 ttCi/ml  [3H]thymidine.  At  the 
indicated  times  after  adding the radiolabel,  cells  were precipitated 
with  cold 10% ~  and incorporation  of  [3H]thymidine  into  DNA 
determined as described in Materials and Methods. The inset shows 
the DNA histograms obtained with flow microfluorimetry of SMCs 
incubated in medium containing 20% FCS with (  ) or with- 
out (  ....  ) 200/~g/ml  beparin  for 72 h. 
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Figure 5. Different species of SMCs respond to different mitogens. 
Growth-arrested SMCs were incubated in medium containing 0.5 % 
plasma-derived  serum  and  [3H]thymidine, along  with  the  indi- 
cated concentrations of  PDGF, EGF, aFGF, bFGF, insulin, or TPA. 
After 36 h, the cells were processed for autoradiography or for scin- 
tillation counting, and the fraction of labeled nuclei and [3H]thy- 
midine incorporation into DNA was determined. 
To  determine  the  appropriate  concentrations  for  each 
mitogen, dose-response experiments were carried out on all 
the  SMC  types,  using  both  [3H]thymidine  incorporation 
into DNA and autoradiographic measurements of the labeled 
nuclei fraction. The data for calf aortic SMCs are typical 
(Fig. 5), and indicate that the optimum concentration of  each 
mitogen is as follows: 30 ng/ml for PDGF, 15 ng/ml for EGF, 
15 ng/ml for both aFGF and bFGF, and 10  -7 M for TPA. In 
experiments with insulin, 5/~M was the concentration used. 
Calf  Aortic SMCs. Calf aortic SMCs were stimulated by 
PDGF, aFGF, bFGF, EGF, and TPA (Figs. 5 and 6 A). Insu- 
lin did not stimulate significant amounts of DNA synthesis 
in these cells, either alone or in combination with any of the 
other mitogens. These results were obtained on cells derived 
from five separate isolation procedures. Heparin (200/~g/ml) 
inhibited the stimulation by PDGF, aFGF, bFGF, and was 
particularly effective in blocking the proliferative response 
to TPA (>t80%). In contrast, heparin only slightly reduced 
(24%) the EGF-induced growth stimulation. 
Rat Aortic SMCs. Rat aortic SMC growth was stimulated 
by PDGE aFGE and bFGF (Figs.  5 and 6 B). This result 
was obtained with cultures derived from seven different iso- 
lations. In six out of seven cultures, the cells were not stimu- 
fated by EGF  (up to  150  ng/ml)  or TPA (up to  10  -5  M); 
SMCs from one of  the seven isolations displayed a significant 
mitogenic response to EGF, but not to TPA. The mechanisms 
underlying the variation in the response of rat aortic SMCs 
('~80% labeled nuclei; Fig.  1 B). In fact, the data indicate 
that the fraction of labeled nuclei peaks at 40% by 28-32 h 
and  does not  rise  significantly after that  (72-h data point 
shown in Fig.  1 B; the same result is obtained at 96 h  [not 
shown]). This clearly demonstrates that cells which initially 
arrest in G~ do not escape and traverse the cell cycle. 
Effect of Heparin on SMC Stimulation by 
Specific Mitogens 
It is generally accepted that regulation of the Go--'S transi- 
tion is under the positive control of peptide growth factors. 
Previous work on the stimulation of SMC proliferation by se- 
rum or purified PDGF indicated that heparin strongly in- 
hibited growth in response to these mitogenic stimuli (Cas- 
tellot et al.,  1987).  However, recent studies in our labora- 
tory on RCECs (Wright et al., 1985) and BALB/c fibroblasts 
(Wright et al.,  1989), and the data of Reilly et al. (1987) on 
calf aortic SMCs indicated that heparin was not effective in 
blocking the proliferative stimulus provided by EGE We there- 
fore undertook a systematic examination of the ability of sev- 
eral purified mitogens to stimulate growth, and the ability of 
heparin to inhibit the mitogenic responses of vascular SMCs 
from several different species and sources. 
Figure 6. Heparin inhibits a PKC-dependent proliferation pathway 
in calf aortic SMCs. The dose-response  data shown in Fig. 6 was 
used to select the optimum concentration for each of the mitogens 
as follows: 30 ng/ml for PDGF;  15 ng/ml for EGF, aFGF, and 
bFGF;  10  -7 M for TPA. Growth-arrested SMCs were incubated in 
0.5% PDS containing 2/~Ci/ml [3H]thymidine  and the above con- 
centrations of mitogens, in the presence or absence of 200/~g/ml 
heparin. After 36 h, cells were processed for scintillation counting. 
All standard errors of the mean are g-l-6%; in calf aortic SMCs, 
difference between the effect of heparin on EGF- and TPA-stim- 
ulated mitogenesis is statistically significant (P < 0.001). 
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rat aortic SMCs, either alone or in combination with any of 
the other mitogens. Heparin was an effective inhibitor of the 
stimulatory response produced by PDGF and the FGFs. 
Human Saphenous  Vein SMCs.  The above results with 
calf and rat  cells  suggested that significant differences  in 
growth response pathways might exist between different spe- 
cies or sources of SMC, and we therefore wanted to test hu- 
man cells (Fig. 5 and 6 C). Human saphenous vein SMC de- 
rived  from three  separate  isolation  procedures  responded 
mitogenically to PDGF, aFGF, bFGF, and EGF, but did not 
synthesize DNA in response to TPA (up to 10  -s M).  Hepa- 
tin effectively blocked  the  growth  response  to all  of the 
stimulatory mitogens, including EGE This is in distinct con- 
trast to the results obtained with calf aortic SMCs (Fig. 5 A) 
and the results previously reported with RCECs and BALB/c 
fibroblasts (Wright et al.,  1985, 1989). 
Heparin Inhibits the Protein Kinase C-dependent 
Pathway in Calf  Aortic SMCs 
Several studies have shown that there are multiple intracellu- 
lar signaling pathways by which cells can respond to mito- 
genic signals. One of these pathways appears to be mediated 
by PKC, whereas another requires cAMP and calcium and 
is the pathway activated by EGE Because TPA directly acti- 
vates PKC, the results obtained with calf  vascular SMCs sug- 
gest that heparin can inhibit the PKC-dependent mitogenic 
response pathway. 
To ensure that the stimulation of mitogenesis seen in the 
presence of TPA was due to its effects on PKC, we tested the 
growth stimulatory properties  of mezerein (a non-phorbol 
ester activator of  PKC) as well as an active and inactive phor- 
bol ester analog (Table I). Mezerein and 4-/~-phorbol 12,13 
didecanoate both stimulate PKC and both were good mito- 
gens for calf aortic SMCs. Heparin was a very effective in- 
hibitor of the mitogenic effects of these two compounds. In 
contrast,  4-ot-phorbol  12,13 didecanoate  did  not activate 
PKC and also failed to stimulate DNA synthesis in calf  aortic 
SMCs. These results suggest that TPA stimulates calf aortic 
SMC mitogenesis via a PKC-dependent pathway, and pro- 
vide additional evidence that heparin is capable of inhibiting 
this pathway. 
To further characterize the effect of  heparin on phorbol es- 
ter-stimulated growth, we determined how long an exposure 
to TPA was required to stimulate calf aortic  SMC growth 
(Fig. 7 A).  For these experiments,  growth-arrested  SMCs 
were exposed to TPA for various times after which the TPA 
was removed and the cultures were fed fresh medium con- 
taining only 0.5 % PDS. [3H]Thymidine  was present through- 
out the experiments; mitogenesis was assessed by measuring 
the incorporation of this radiolabeled precursor  into DNA. 
Half-maximal stimulation of DNA synthesis was achieved 
after a 15-rain  exposure to TPA; maximal stimulation required 
a 1-2-h exposure. To compare the kinetics of heparin inhibi- 
tion of serum-stimulated growth with TPA-stimulated  growth, 
we carded out the "delayed addition" experiments (Fig. 7 B) 
described  above. TPA was added  to quiescent  calf aortic 
SMCs, and at the indicated times after TPA exposure, 200 
/~g/ml heparin was added to the cultures.  Heparin addition 
to TPA-treated calf aortic SMC8 could be delayed for up to 
8 h, or until ,x,4 h before S phase, and still inhibit DNA syn- 
Table L Effect of  Phorbol Ester Analogs and Mezerein on 
Calf  Aortic SMC Proliferation 
cpm/lO  s Cells (x  l0  s) 
Concentration  -  HEP  + HEP 
M 
TPA  10  -9  4.51  0.98 
10  -s  8.93  1.36 
10  -7  9.27  1.41 
10  -6  8.68  1.50 
~/-PDD  10  -9  2.36  0.89 
10  -s  5.07  1.31 
10  -7  7.24  1.47 
10  -6  7.92  1.38 
Mezerein  10  -~  5.89  1.29 
10  -s  9.76  1.79 
10  -7  9.70  1.68 
10  -6  9.83  1.85 
c¢-PDD  10  -9  0.72  0.48 
10-'  0.80  0.37 
10  -7  0.85  0.59 
10  -6  0.69  0.42 
Growth-arrested  calf aortic SMCs were exposed to DME  +  0.5%  PDS con- 
mining 2 /~Ci/ml [3H]thymidine and the  indicated concentrations  of phorbol 
ester analogs or mezerein in the presence or absence of 200/~g/ml heparin. Af- 
ter 36 h, the cells were processed for scintillation counting. SMCs exposed to 
DME  +  0.5%  PDS alone incorporated  0.63  x  lO  s cpm/lOs cells.  Cultures 
exposed  to normal growth medium (DME  +  10%  calf serum) incorporated 
11.4  x  lOs cpm/los cells,  c~-PDD, 4-ct-phorbol  12,13-didecanoate; [3-PDD, 
4-/3-phorbol 12,13-didecanoate. 
thesis. This observation parallels the results for serum-stim- 
ulated growth (Fig. 2 A). 
Discussion 
In this communication,  we have analyzed the mitogenic re- 
sponses of  vascular SMCs derived from different species, in- 
cluding human, and have further examined the role of hepa- 
rin as an inhibitor of SMC proliferation. 
In all SMC types, heparin was able to strongly inhibit the 
mitogenic response to PDGF, aFGF, and bFGE In calf  aortic 
SMCs,  heparin  strongly inhibited TPA-stimulated growth, 
but  was  much less  effective in blocking  EGF-stimulated 
mitogenesis.  It is  now appreciated  that the mitogenic re- 
sponse of cells may follow multiple postreceptor pathways. 
One growth response pathway is dependent upon protein ki- 
nase C, and is activated by PDGF, bombesin, thrombin, and 
phorbol esters. This pathway appears to be strongly inhib- 
ited by heparin in calf aortic SMCs and BALB/c fibroblasts 
(Wright et al., 1989). The other pathway is dependent upon 
cAMP  and calcium,  and is the pathway used by EGF in 
fibroblasts. This pathway appears to be relatively insensitive 
to  heparin  in  calf aortic  SMCs  and  BALB/c fibroblasts 
(Wright et al., 1989). The difference between the effect of 
heparin on EGF- and TPA-stimulated mitogenesis is statisti- 
cally highly significant (P <  0.001). Further evidence sup- 
porting  the idea of a pathway-selective effect of heparin  is 
provided  by  our  observations  that  heparin  blocks  TPA- 
stimulated induction of c-fos and c-myc mRNA in SMCs and 
in BALB/c fibroblasts, but does not inhibit EGF-stimulated 
expression of these protooncogene mRNAs (Castellot et al., 
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Figure  7.  Kinetics  of TPA-stimulated SMC  proliferation.  (A) 
Growth-arrested calf aortic SMCs were incubated in medium con- 
mining 0.5% plasma-derived serum, 2 ttCi/ml [3H]thymidine,  and 
10  -7 M TPA. Control cells were incubated in medium containing 
10% calf serum [3H]thymidine. At the indicated times, the cells 
were processed for scintillation counting. (B) The "delayed addi- 
tion" experiment described in Fig. 2 was carded out using TPA as 
the growth stimulus rather than serum. Growth-arrested  calf aortic 
SMCs were incubated in medium containing 0.5 % plasma-derived 
serum, 2 #Ci/ml  [3H]thymidine, and 10  -7 M TPA. At the indi- 
cated times, 200/zg/ml heparin was added to the cells. After 36 h, 
the cells were processed for scintillation counting. 
1988; Wright et al., 1989; Pukac, L. A., J. J. Castellot, T. C. 
Wright, B. L. Caleb, M. J. Karnovsky, manuscript submitted 
for publication).  It should be  noted that EGF-stimulated 
mitogenesis is partially inhibited by beparin. One explana- 
tion for this observation is that EGF may work via multiple 
intracellular signaling pathways, only one of which is hepa- 
rin sensitive. Another possibility is suggested by our cell cy- 
cle data; namely, that heparin may block two or more sites 
within the cell cycle, only one of which is EGF driven. 
In rat SMCs, heparin inhibits the mitogenic response to 
PDGE aFGE and bFGE all of which are thought to activate 
the PKC-dependent pathway. Molecular analysis has shown 
that heparin blocks TPA-, but not EGF-stimulated induction 
of c-fos and c-myc gene expression (Castellot et al.,  1988; 
Pukac, L. A., J. J. Castellot, T. C. Wright, B. L. Caleb, M. J. 
Karnovsky, manuscript submitted for publication), indicating 
pathway-selective inhibition by heparin in this SMC type as 
well. These observations also suggest that PKC is activated 
in these cells, but that treatment with TPA or EGF alone is 
not sufficient to generate a full mitogenic response.  The ques- 
tion of  whether heparin acts on PKC directly has not been ad- 
dressed in SMCs. However, in BALB/c cells, heparin does not 
inhibit PKC directly, but appears to act at a site distal to this en- 
zyme in the mitogenic response pathway (Wright et al., 1989). 
An interesting feature of the pathway-specific nature of 
heparin's  antiproliferative effect is  that in  human SMCs, 
heparin is able to block the mitogenic stimulus provided by 
EGE  Similar results have been observed in baboon aortic 
SMCs (Kenagy, R. D., and A. W. Clowes, unpublished ob- 
servations). The reasons for this are not clear, but several 
possibilities exist. For example, as noted above,  EGF itself 
might be able to use several different intracellular signaling 
pathways, including heparin-sensitive and -insensitive types 
which are activated preferentially in different cell types. Al- 
ternatively, some other property intrinsic to human and ba- 
boon  SMCs  might  permit  heparin  to  inhibit  the  EGF- 
mediated growth pathway in these cell types. 
The  experiments  with  specific mitogens were  also de- 
signed to resolve a  puzzling set of observations.  We had 
reported that the serum-stimulated growth of RCECs was in- 
hibited by heparin, but the EGF-stimulated proliferation of 
these cells was much less sensitive to heparin (Wright et al., 
1985).  Rat aortic SMC proliferation was not stimulated by 
EGE  Subsequently, Reilly et al.  (1987)  reported that calf 
aortic SMCs did respond mitogenically to EGF,  and that 
heparin again was relatively ineffective at blocking EGF- 
stimulated growth.  We therefore reasoned that significant 
differences might exist in the growth factor responsiveness 
of different species and sources of vascular SMCs, and per- 
formed experiments designed to test this possibility. When 
a panel of purified mitogens were tested for their ability to 
stimulate the proliferation of SMCs derived from rat, calf, 
and human vessels,  distinct species  differences were ob- 
served 0~ig. 5). Rat aortic SMCs responded mitogenically  to 
PDGF,  aFGF,  and  bFGF;  human  saphenous  vein  SMC 
growth was promoted by PDGF, the FGFs, and EGF; and 
calf  aortic SMC proliferation was enhanced by PDGF, FGFs, 
EGF, and phorbol esters. 
It is important to consider the precise experimental context 
in which our mitogen studies are carded out. In the present 
experiments, the growth factors are added to Go cells indi- 
vidually and the mitogenic response is determined. Insulin 
was the only agent tested in combination with other growth 
factors;  it was unable to  stimulate DNA  synthesis either 
alone or when combined with any of the other mitogens. It 
is possible that EGF and TPA are unable to stimulate rat 
SMC DNA synthesis alone, but could stimulate rat SMC 
growth in combination with other factors. For example, rat 
aortic SMCs do not respond to EGF alone, but the combina- 
tion of EGF and thrombospondin does promote DNA syn- 
thesis in this SMC type (our unpublished data), in agreement 
with the data of Majack et al.  (1986).  Alternatively, the 
different responsiveness  to  mitogens  could  indicate  that 
different growth pathways are operant in different species or 
sources of SMCs. Clearly, it will be important to explain the 
species and vessel source differences observed. Experiments 
designed to do this are under way. 
The cell cycle experiments provide new information and 
help clarify certain issues raised by previous studies. Our 
earlier cell cycle kinetic experiments (Castellot et ai., 1985a) 
on rat aortic SMCs in which the addition of heparin was 
delayed after growth stimulation indicated a late G, block, 
but the 4-6-h time points used allow the heparin-sensitive 
point to fall within a range of 0 to 6 h before S phase. Using 
the "delayed addition" approach (with 4-h time points) in ba- 
boon aortic SMCs, it was found that the heparin-sensitive 
point in this species of SMCs was 4-8 before the onset of 
DNA synthesis (Kenagy, R. D., and A. W. Clowes, unpub- 
lished data). The experiments reported here used 0.5-1.0-h 
time points in both rat and calf  aortic SMCs, allowing greater 
precision in localizing the heparin-sensitive block point. For 
both these SMC types, heparin was required only during the 
last 4 h before S phase, and this was corroborated by an inde- 
pendent experimental approach. The temporal correlation of 
the late G, block by heparin and the serum-sensitive point 
in calf aortic SMCs (Fig. 3; Campisi and Pardee, 1982) sug- 
gests the possibility that heparin may exert its effect in late 
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genic pathway. These results are in reasonably good agree- 
ment  with  the  baboon  aortic  SMC  data  of Kenagy  and 
Clowes, especially given that intrinsic  species-specific dif- 
ferences  in cell cycle kinetics  and mitogenic response path- 
ways clearly  exist. Other work (Seldon, S. C., unpublished 
observations)  also suggests a late Gl heparin-sensitive  point 
in human aortic SMCs, but the precise location of the block 
was not determined. 
Our data also indicate that SMCs continuously exposed to 
heparin do not remain blocked in the latter part of Gin, but 
instead move slowly back to Go. Thus, if heparin-containing 
medium is replaced after 72 h with normal growth medium, 
rat aortic SMCs required 16 h to begin DNA synthesis,  the 
same length  of time  required by  serum-stimulated  SMCs 
never exposed to heparin.  Seldon has reported that human 
aortic SMCs exposed to heparin also return to the Go state 
(unpublished data), although it appears that very short (<1 h) 
exposures to heparin  rapidly  induce  the cells to return to 
Go. The reasons for this difference  in the kinetics of return 
to quiescence are not clear, but may reflect a species differ- 
ence or may be due to differences  in the experimental  pro- 
tocols used. 
The substantial reduction  in the fraction of cycling  cells 
seen at higher doses of heparin has been previously observed 
by  several  investigators  (Castellot  et  al.,  1985a;  Kenagy, 
R. D., and A. W. Clowes, unpublished;  Seldon, S. C., un- 
published); however, the delayed entry of SMCs into S phase 
in the presence of heparin (Fig.  1) has not been reported. It 
should be noted, however, that this observance of a dual ef- 
fect of heparin on the Go~S transition is highly concentra- 
tion dependent. 
Recent results from our laboratories indicate that in addi- 
tion to blocking growth late in Gt, heparin also affects very 
early Go~G, growth-related events,  suggesting  that heparin 
may inhibit proliferation by multiple mechanisms. For exam- 
ple, cell cycle analysis suggests an early Gj block in RCECs 
(Wright and Karnovsky, 1987). We also examined the effect 
of heparin on the expression of c-fos and c-myc, two "imme- 
diate-early" protooncogenes that appear to be critical for cell 
proliferation (Armelin et al., 1984; Miller et al., 1984; Holt 
et al., 1986; Heikkila et al., 1987). The results indicate that 
both c-fos and c-myc mRNA induction are inhibited by hepa- 
rin in rat and calf SMCs and BALB/c  cells (Wright et al., 
1989).  The ability  of heparin to inhibit protooncogene ex- 
pression in these three cell types is pathway selective, since 
induction of c-fos and c-myc by serum and TPA are inhibited 
by heparin, but the induction of these genes by EGF is un- 
affected. These data, in combination with the dual effects of 
heparin on the Go--'S transition indicated by the cell cycle 
kinetic  studies,  provide further evidence for the possibility 
of multiple targets for the antiproliferative mechanism of ac- 
tion of heparin. 
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